98 results about "Transmissible disease" patented technology

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

The invention provides a method and a kit for quantitative detection of recombinant redistribution of a Databa virus based on a multiple digital PCR (Polymerase Chain Reaction) technology, and belongs to the field of infectious disease monitoring. The method comprises the following steps: providing a to-be-detected sample containing segmented viruses and viral nucleic acid; detecting nucleic acid by using a plurality of multiple digital PCR reaction systems containing specific primer pairs and fluorescence labeled probes; amplifying according to a fluorescence coding rule, collecting and analyzing multi-channel fluorescence signals, and calculating the absolute copy number of each genotype; and based on copy number analysis genotype intra-fragment distribution proportion and inter-fragment combination mode, evaluating characteristics and frequency of virus recombination reconfiguration events. According to the detection method and the kit provided by the invention, accurate quantification of all main genotypes of the Databa virus can be realized.

The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and / or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

A combined Chinese yam tuber growth groove arranged in a trench belongs to agricultural planting appliances, the Chinese yam tuber growth groove comprises a combination part, a space part and a base, the combination part is used for overlapping an upper Chinese yam tuber growth groove and a lower Chinese yam tuber growth groove, and the Chinese yam tuber growth grooves are combined to form a Chinese yam tuber growth space. According to the Chinese yam tuber growing device, Chinese yam tubers are separated from soil, occurrence of soil infectious diseases is avoided, growth resistance of the Chinese yam tubers is reduced, and the Chinese yam tuber growing device has the advantages that the Chinese yam tuber growing device is simple in structure, convenient to use and high in yield, and the yield of the Chinese yam tubers is increased. Chinese yam tubers grow in the shallow soil layer, the planting density is increased, the tower furrow phenomenon is avoided, the yield and quality of Chinese yams are improved, the plot planting limitation is overcome, the planting range is expanded, mechanical planting is achieved, and the income of farmers is increased.

The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.

Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease. Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-y-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]

Disclosed are substituted indole compounds and compositions. The substituted indole compounds and compositions can be used for treating or preventing acute renal failure in a subject. The compounds and compositions can also be used for treating an infectious disease or cancer.

The present invention provides an mRNA element, a system, and a use. A UPA-containing uncapped linear mRNA of the present invention can be efficiently and stably expressed without adding a 5' cap or adding a nucleic acid modification in an in vitro transcription synthesis process, and can be used as an infectious disease vaccine or tumor vaccine expression system.

The application of unilateral or bilateral permanent prostheses to the labium majus in the external genitalia of women for reconstructive and aesthetic purposes may make it appear fuller. The labium majus may lose its fullness and symmetry due to menopause, rapid weight gain and loss, traumas, cancers, and infectious diseases. Aesthetic interventions (e.g., hyaluronic acid filler injection and fat grafting) aiming to provide the labium majus with fullness have become very popular in recent years. The hyaluronic acid filler is used for reconstructive purposes to achieve fullness in labium majus. However, the maximum amount that can be injected is 3 mL, which is often insufficient for the desired outcome and its effect lasts for a maximum of 1 year. Autologous fat grafting is administered by taking 18–120 mL of fat from patients themselves; however, its effect usually lasts 1 to 4 years. The application of a prosthesis will provide labium majus with fullness and this effect will be long-lasting. The outer edge of the prosthesis is convex and the inner edge is concave. In male genitalia, prostheses have been used since 1950 to provide the testicles with fullness. Scientific studies have shown that these prostheses positively affect self-confidence and body perception indices in men.

The invention provides a targeted mRNA delivery system of muscle tissues and / or muscle cells based on aptamer functionalized LNP (Apt-LNP), the delivery system can significantly improve mRNA transfection of the muscle tissues, and meanwhile, mRNA expression in main organs such as liver and spleen is greatly reduced. The expression intensity of muscle tissue in-situ mRNA is improved through modification of the aptamer, meanwhile, mRNA expression in main organs such as the liver and the spleen is greatly reduced, and side effects caused by off-target of mRNA infectious disease vaccines are expected to be avoided. The method is expected to be applied to the field of infectious disease mRNA vaccines The invention also provides a targeting mRNA delivery system of lymph node tissues and / or immune cells based on the aptamer functionalized LNP (Apt-LNP). Compared with an existing lymph node targeting system, the Apt-LNP modified by the aptamer not only can realize lymph node mRNA targeting, but also can further target immune cells, and is expected to be applied to the field of tumor mRNA vaccines to enhance the curative effect of tumor vaccines.

An immunotherapeutic mRNA vaccine comprises a first translation unit comprising a secretable first fusion protein comprising a co-stimulatory molecule fused to a first TAA, adapted to generate a first TAA specific adaptive immune response by way of a first immunostimulatory pathway. The immunotherapeutic mRNA vaccine also comprises a second translation unit comprising a non-secretable second fusion protein comprising an identical co-stimulatory molecule fused to a second TAA identical to the first TAA, adapted to generate a second TAA specific adaptive immune response by way of a second immunostimulatory pathway, whereby the at least two immune response interact at one or more locations downstream to amplify the first TAA specific adaptive immune response.

The application relates to the diagnosis and treatment of diseases, including cancer, chronic infectious diseases, autoimmune diseases, inflammatory disorders, as well as the prevention of transplant rejection. The invention provides, and involves the use of, antibody molecules that bind CD28 in a non super-agonistic manner and which also bind to CTLA-4. The antibody molecules may form part of a bispecific molecule which binds e.g. a tumor associated antigen or a further T cell antigen, such as CD3.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure relates to methods, compositions, and kits for enriching and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide kits including one or more ATPS compositions, a binding buffer, and a solid phase medium. Other embodiments provide methods for treating cancer or an infectious disease in a patient in need thereof.

Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and / or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

The disclosure is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytokines. The disclosure relates to a novel SPD-TNFSF fusion protein including a TNF-superfamily (TNFSF) ligand, or receptor binding domain thereof, fused to a coiled-coil domain of surfactant protein-D (SPD). Also provided a trimeric or multimeric fusion protein including a plurality of SPD-TNFSF fusion proteins. The disclosure also provides an expression vector as mRNA, plasmid or virus including an isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or a pharmaceutical composition including thereof.

An immunosuppressant having the structure of formula (I), and a preparation method therefor and the use thereof are provided. The series of compounds can be widely used in the preparation of drugs for preventing and / or treating cancers or tumors, immune-related diseases and disorders, communicable diseases, infectious diseases or metabolic diseases mediated by PD-1 / PD-L1 signal pathways, which drugs are expected to be developed into a new generation of PD-1 / PD-L1 inhibitors.

The present disclosure provides nucleic acid molecules (e.g., a plasmid or vector) comprising a nucleic acid sequence encoding a bicistronic or multicistronic LAMP Construct comprising specific fragments of the LAMP luminal domain and an antigenic domain heterologous to the LAMP protein to provide at least one antigen for priming an immune response, wherein the antigen expressed by the Construct is optionally processed and presented to MHC class II molecules, and also a nucleic acid sequence encoding an immune response enhancing polypeptide that is optionally secreted from a host cell. The nucleic acid molecules can be used, for example, for the treatment of disease and in particular, allergies, infectious disease, diabetes, hyperproliferative disorders and / or cancer.

The invention discloses a noninvasive respiratory virus aerosol enrichment detection device. The noninvasive respiratory virus aerosol enrichment detection device comprises a mouthpiece type aerosol collection interface and a rear-end filter, a thick round pipe section, a contraction conical pipe section and a thin round pipe section are sequentially connected in the blowing nozzle type aerosol collecting connector, the rear-end filter is arranged on the outer wall of the thin round pipe section in a sleeved mode, an annular protrusion is arranged on the inner wall of the middle section of the rear-end filter, and one end of the rear-end filter is fixedly connected to the outer wall of the upper end of the thin round pipe section. The tail end of the thin round pipe section abuts against the annular protrusion, the filter at the rear end is blocked by a composite activated carbon protection layer, and the upper end of the thin round pipe section is blocked by non-woven fabric; the micro-fluidic enrichment module integrated with the nano-porous detection membrane is arranged between the composite activated carbon protection layer and the non-woven fabric in the thin round pipe section, and an enriched sample output by the micro-fluidic enrichment module is communicated with the detection interface, so that a high-sensitivity detection tool is provided for prevention and control of respiratory infectious diseases, and dual requirements of timeliness and universality are met.

Provided herein are compositions comprising macromolecular photocleavable prodrug compounds of Formula (I), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, and isotopically enriched derivatives thereof. Also provided are methods, uses, pharmaceutical compositions, and kits involving the inventive compounds or compositions for treating and / or preventing a disease and / or condition (e.g., inflammatory disease, infectious disease, pain) in a subject, optionally comprising illumination of the compound, composition, or pharmaceutical composition with light of an absorption wavelength sufficient to cleave the bonds between each instance of L and each instance of X upon illumination with the light (e.g., light between approximately 200 nm to 500 nm).

The present disclosure provides nucleic acid molecules (e.g., a plasmid or vector) comprising a nucleic acid sequence encoding a bicistronic or multicistronic LAMP Construct comprising specific fragments of the LAMP luminal domain and an antigenic domain heterologous to the LAMP protein to provide at least one antigen for priming an immune response, wherein the antigen expressed by the Construct is optionally processed and presented to MHC class II molecules, and also a nucleic acid sequence encoding an immune response enhancing polypeptide that is optionally secreted from a host cell. The nucleic acid molecules can be used, for example, for the treatment of disease and in particular, allergies, infectious disease, diabetes, hyperproliferative disorders and / or cancer.

Disclosed are compositions and methods for activating NLRP12 and / or NLRC5 and inflammatory cell death using heme and at least one PAMP and / or DAMP molecule.Also provided are screening assays for identifying NLRP12 and / or NLRC5 inhibitors, and the use of such inhibitors in treating or alleviating NLRP12-mediated or NLRC5-mediated inflammation associated with hemolytic disease, infectious disease, cancer, or inflammatory syndrome.

Providing a binder and a method for using the same. [Solution] The present invention provides conjugates that specifically bind to CD8+KIR+T regulatory cells, and their use in the treatment of diseases or disorders, such as inflammatory diseases, autoimmune diseases, cancer, or infectious diseases. Conjugates and methods of using them to modulate the activity of CD8+KIR+ regulatory T cells (Tregs) are provided herein. The conjugates are bispecific or polyspecific and specifically bind to antigens expressed on the surface of CD8+KIR+Tregs.

Disclosed are transmissible disease stethoscope protective barrier / shield devices. A device for transmissible disease protection is described. The device can include a shield or barrier and a dispenser. The shield or barrier may be housed within the dispenser. The shield or barrier may be foldable, folded, or unfolded around a stethoscope.

The present invention relates to a composition comprising a polymer of formula (I) and one or more compounds of formula (II) or formula (III), and to its use in the treatment of diseases (e.g., cancer, cardiovascular disease, infectious disease, or neurodegenerative disease). The polymer of formula (I) and one or more compounds of formula (II) or formula (III) have the following structure [Formula 1] Represented by JPEG2026513146000041.jpg60159, A, E, Z, Z', R1, R2, R3, R3', R4, R4', R5, R6, R7, R8, R9, R 10 n, m, a, y, and q are as defined in the specification.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, ----, R1, R2, R3, R4, R1, R6, R7, R1, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

A method and apparatus for detecting one or more target analytes in a sample, the apparatus comprising: (i) a sample container for encapsulating a sample mixture comprising the sample and at least one lysis reagent; (ii) at least one vacuum blood collection tube sealed under negative pressure using a sealing element and containing a stabilizing reagent corresponding to at least one of the target analytes being detected; and (iii) at least one fluid communication channel oriented to enable the sample mixture to be fluidly connectable from the sample container to one or more of the at least one vacuum blood collection tube via the sealing element of each such fluidly connected vacuum blood collection tube, wherein establishing an fluidly connectable connection with the at least one vacuum blood collection tube sealed under negative pressure causes at least some of the sample mixture to communicate from the sample container to the at least one such fluidly connected vacuum blood collection tube.

Provided herein are thiazole amide compounds (e.g., Formula (I)) for use in enhancing human immune response and / or as adjuvants in vaccines. The compounds described herein are used as enhancers of an immune response (e.g., innate and / or adaptive immune response), and are useful in treating and / or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are compositions (e.g., pharmaceutical composition), kits, methods, and uses including or using compounds described herein.